Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing molecules by applying its technology to the discovery of novel targets and drugs.
Salt Lake City, Utah-based Recursion is built upon an AI-powered approach to phenotypic screening and other aspects of the drug discovery process. The approach is underpinned by a fast-growing collection of cellular images and other data. By analyzing this resource with software incorporating computer vision, machine learning and neural networks, Recursion thinks it can spot changes in its data and, in doing so, discover novel biology, targets and drugs.